Ruof, Jörg; Schwartz, Friedrich; Schulenburg, J.-Matthias - In: The European Journal of Health Economics 15 (2014) 6, pp. 577-589
Considerable variance was observed in the levels of additional benefit reported by pharmaceutical manufacturers, IQWiG and G-BA. The areas of disagreement included ACT selection, definition of subgroups and patient-relevant endpoints, and classification and balancing of adverse events. </AbstractSection>...